NPPA Extends Knee Implant Price Cap by Two Months Until Jan 15

By The Indus Pulse Editorial Team3 min read
A metallic orthopaedic implant resting on a blue surgical drape with several surgical instruments
AI illustrationCreated for The Indus Pulse with AI tools

The National Pharmaceutical Pricing Authority (NPPA) has extended existing ceiling prices on orthopaedic knee implants by two months until January 15, 2027, via a Press Gazette notification, according to The Economic Times and Medical Buyer. Unlike the previous full-year renewal issued on November 14, 2025, which was valid until November 15, 2026, this shorter extension comes while the regulator reviews representations from manufacturers and industry associations, Medical Buyer and The Economic Times reported.

Industry Split Over Margins and Cementless Implants

Importers and manufacturers have urged the NPPA to remove or relax the price cap, citing foreign exchange volatility, higher manpower and freight expenses, a rising Wholesale Price Index, and supply chain disruptions, Medical Buyer reported. A separate request for a distinct price ceiling on cementless knee implants remains pending after the NPPA's Multidisciplinary Committee of experts deferred a decision on February 11, 2026, according to Medical Buyer. Conversely, domestic MedTech body the Association of Indian Medical Device Industry (AiMeD), whose Forum Director Rajiv Nath welcomed the extension, favours retaining caps while demanding trade margin rationalisation, The Economic Times and Medical Buyer reported.

2017 Cap Background and Supreme Court Scrutiny

The NPPA first imposed knee implant ceilings on August 16, 2017, under Paragraph 19 of DPCO 2013 after finding irrationally high trade margins, cutting standard cobalt-chromium systems from about Rs 1.58 lakh to Rs 54,720 and capping titanium and oxidised zirconium systems at Rs 76,600 in a market performing over 250,000 knee replacements annually, Medical Buyer reported. The extension also coincides with Supreme Court scrutiny in a public interest petition filed by Kishan Chand Jain before Justices Vikram Nath and Sandeep Mehta, alongside NPPA's November 9 Paragraph 19 cap limiting trade margins on 137 non-scheduled anti-cancer drugs to 30% of MRP and its June 50% ceiling hike for cisplatin and carboplatin after a surge in platinum costs caused shortages, according to Medical Buyer. Medical Buyer noted that AiMeD wants the regulator to scrutinise three areas: government and Ayushman Bharat PM-JAY supply prices, the spread separating MRP or ceiling rates from price to distributor (PTD) levels, alongside patient affordability and access to advanced medical technologies. The 2017 order cut standard cobalt-chromium knee system prices by roughly 65% from an average MRP of about Rs 1.58 lakh, while November 9's 30% anti-cancer margin cap covers over 1,300 brands and dosage forms, Medical Buyer reported.

Background

According to data submitted by manufacturers and importers for July 2018 to June 2019, knee implant sales rose 30%.

On September 14, 2026, NPPA directed Total Knee Replacement System manufacturers and importers to submit detailed knee implant data via the IPDMS 2.0 portal and email by 30 September 2026, according to CliniExperts.

Under the Central Government Health Scheme (CGHS) schedule effective 13 October 2025, the notified semi-private-ward rate for unilateral total knee replacement is ₹1,52,000 in Tier-X metro NABH hospitals, according to Aarogyam Surgicare.

Spotted an error in this article? Tell us and we will check it.